Drug utilization review (DUR) is defined as an authorized, structured, ongoing review of prescribing, dispensing and use of medication. DUR encompasses a drug review against predetermined criteria that results in changes to drug therapy when these criteria are not met.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
Medication errors are among the most common medical errors, harming at least 1.5 million people every year. The extra medical costs of treating drug-related injuries occurring in hospitals alone are at least to $3.5 billion a year, and this estimate does not take into account lost wages and productivity or additional health care costs.
Sponsored webinar that provided an overview of key pharmacist-specific considerations for biosimilars, including details of the approval process, considerations for appropriate use, and practices that mitigate inadvertent substitution and encourage accurate adverse event reporting.
Where We Stand: AMCP supports the use of therapeutic interchange programs as a part of a comprehensive approach to quality, cost‐effective patient care.
